Details of the Drug

General Information of Drug (ID: DMPYQ7B)

Drug Name
Trimebutine
Synonyms
Trimebutine maleate; Trimedat; Dromostat; Ibutin; Digerent polifarma; EINECS 251-845-9; TM 906; (1-Ethyl-1-phenyl-2-(3,4,5-trimethoxybenzoyloxy)ethyl)dimethylammonium hydrogen maleate; AC1O5HFA; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethylphenethyl ester, maleate (1:1); 34140-59-5; SCHEMBL1652810; C22H29NO5.C4H4O4; AKOS026750056; LS-38470; dimethyl-[2-phenyl-1-(3,4,5-trimethoxybenzoyl)oxybutan-2-yl]azanium; (E)-4-hydroxy-4-oxobut-2-enoate; Benzoic acid, 3,4,5-trimethoxy-, beta-(dimethylamino)-beta-ethyl
Indication
Disease Entry ICD 11 Status REF
Irritable bowel syndrome DD91.0 Approved [1]
ATC Code
A03AA05: Trimebutine
A03AA: Synthetic anticholinergics, esters with tertiary amino group
A03A: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A03: DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A: ALIMENTARY TRACT AND METABOLISM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 387.5
Logarithm of the Partition Coefficient (xlogp) 4
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Elimination
Renal elimination is predominant while excretion into feces is also observed (5-12%) [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1 hour [2]
Metabolism
The drug is metabolized via the hepatic [3]
Chemical Identifiers
Formula
C22H29NO5
IUPAC Name
[2-(dimethylamino)-2-phenylbutyl] 3,4,5-trimethoxybenzoate
Canonical SMILES
CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C
InChI
InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3
InChIKey
LORDFXWUHHSAQU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5573
ChEBI ID
CHEMBL190044
CAS Number
58997-89-0
UNII
QZ1OJ92E5R
DrugBank ID
DB09089
TTD ID
D0E0CT
INTEDE ID
DR1646
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997 Sep-Oct;25(5):225-46.
3 Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 1;17(5):1131-9. doi: 10.1158/1078-0432.CCR-10-1220. Epub 2011 Jan 10.
4 Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.